Amgen Inc.'s arbitration against Johnson & Johnson over epoetin alfa ended with a bang - the pharmaceutical company must pay Amgen $150 million - but who (if anyone) should whimper was uncertain, since Amgen had asked for much more. (BioWorld Today)